We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CorePharma Petitions FDA to Investigate Endo’s 2010 Moban Withdrawal
CorePharma Petitions FDA to Investigate Endo’s 2010 Moban Withdrawal
June 7, 2013
Seeking an avenue for a possible ANDA approval, CorePharma has petitioned the FDA to investigate whether Endo Pharmaceuticals discontinued its antipsychotic drug Moban in 2010 for reasons of safety and effectiveness, or as the generic drugmaker suspects, due to sourcing issues.